Compare Ascendis Pharma A/S (ASND) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Realty Income Corp — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Realty Income Corp trades at $63.31 (market cap $59.04B). The key difference: Realty Income Corp is far larger — about 3.3× Ascendis Pharma A/S's market cap, and Realty Income Corp pays a 5.14% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | O | |
|---|---|---|
Market Cap | $17.74B | $59.04B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $67.56 |
52-Week Low | $163.32 | $55.93 |
Enterprise Value | $18.11B | $88.84B |
Dividend Yield | — | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Realty Income (O) trades at $63.31, up 0.22% on the day, with a bullish technical signal from moving averages and strong support at $63. The company shows robust revenue growth, reaching $5.75B in 2025, and maintains a high gross margin of 92.54%, though it has missed recent EPS estimates. Dividend payments remain consistent at $0.27 monthly, supporting income-focused strategies.
Outlook is cautiously optimistic with a consensus price target of $67.86, offering ~7% upside. Risks include rising debt levels and interest expense, but strategic expansion into data centers and high occupancy rates provide stability. Analyst sentiment is mixed with 41% buy ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
